李仁妮博士加入GRACE，担任客座教授，为普通话社区提供最新信息给我们的普通话肺癌视频库。
在此视频中，李医生分享了晚期NSCLC和高肿瘤PD-L1表达患者的主要治疗选择的信息。
Dr. Jenni Li joins GRACE as guest faculty to provide updated information to our Mandarin Lung Cancer Video Library, for our mandarin speaking community.
In this video, Dr. Li shares information on the leading treatment options for patients with advanced NSCLC and high tumor PD-L1 expression.
For more, please visit cancerGRACE.org/. To join the conversation, visit cancergrace.org/forum.
- The Leading Treatment Options for Advanced NSCLC and High PDL-1 - Mandarin Lung Cancer Video Library ( Download)
- Lung Cancer Video Library - Das - Targeted Therapies NSCLC PDL1 Expression Leading Treatment Options ( Download)
- Treatment Options, Low or Negative PDL1 Advanced Squamous NSCLC - Mandarin Lung Cancer Video Library ( Download)
- Lung Cancer Video Library - Das - Treatments - Low or Negative PDL1 and Advanced Non-Squamous NSCLC ( Download)
- Advanced NSCLC Candidates for First Line Immunotherapy Alone - Mandarin Lung Cancer Video Library ( Download)
- Can Immunotherapy Help Frail Patients with Advanced NSCLC - Mandarin Lung Cancer Video Library ( Download)
- How to Select the Right Immunotherapy for First-Line Treatment of Advanced NSCLC ( Download)
- How to Select the Right Immunotherapy for First-Line Treatment of Advanced NSCLC ( Download)
- Gaining an Advantage Over NSCLC: How to Achieve the Greatest Benefit With Immunotherapy ( Download)
- Basic Principles of Managing Locally Advanced NSCLC ( Download)
- Chemo + I-O in Frontline mNSCLC: PD-L1 TPS 1%-49% ( Download)
- Immunotherapy for Patients with Driver Mutation - Lung Cancer Video Library ( Download)
- PD-L1 Less Than 49%: Available Treatments ( Download)
- The role of PD-L1: is it accurate enough as a biomarker for immunotherapy response ( Download)
- Dr. David Spigel, Part 2: Optimal Duration for Immunotherapy with Advanced Lung Cancer ( Download)
